BioSpace News Archive

Poseida Therapeutics, Inc. today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today at 10:00am ET / 7:00am PT.

Ansa Biotechnologies today announced the appointment of Matthew F. McManus, M.D, Ph.D., as Independent Director and Chairperson of the company’s Board of Directors.

Biofrontera Inc. today announced that it will report financial results for the three and 12 months ended December 31, 2022 on Wednesday, March 8, 2023.

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2022 financial and operating results on Wednesday, March 1, 2023.

Cardio Diagnostics Holdings Inc to Debut PrecisionCHD ™ at the American College of Cardiology’s 72nd Annual Scientific Session.

Impact BioMedical and its research partner Global Research and Discovery Group today announced that they have finished the first phase of a groundbreaking project that could give humans the edge over cancer.

ChromaDex Corp., a global bioscience company dedicated to healthy aging, holds an exclusive license from Queen’s University Belfast for methods of making nicotinamide riboside and related derivatives, some of the most efficient nicotinamide adenine dinucleotide precursors, and announced it expanded this patent family with newly granted U.S. Patent 11,584,770 for purity compositions of dihydronicotinamide riboside and dihydronicotinic acid riboside.

Quoin Pharmaceuticals Ltd. today announced the pricing of its “reasonable best efforts” public offering of 24,750,000,000 ordinary shares.

AllCells®, a Discovery Life Sciences™ company and leading provider of critical starting material and services for cell and gene therapy, has announced the expansion of its apheresis network with the addition of two new centers in Houston, Texas, and Huntsville, Alabama.

Alteogen Inc. (KOSDAQ:196170) (“Alteogen”), a leading biotechnology company based in South Korea, provided a patient enrollment update for the company’s ongoing Phase 3 study of ALT-L9 for the treatment of neovascular age-related macular degeneration (wet AMD).